CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
Latest Information Update: 10 Mar 2026
At a glance
- Drugs AAV9 follistatin gene therapy Unlimited Biotechnology (Primary)
- Indications Sarcopenia
- Focus Adverse reactions
- Acronyms CALM-AF-AI
- Sponsors Unlimited Biotechnology
Most Recent Events
- 10 Mar 2026 New trial record